Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 10/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.50 |
| ▸ | ITGAL | P20701 | 3/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355176 | 0.91 | ITGB2 (0.59) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL23355175 | 0.91 | ITGB2 (0.59) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL24009788 | 0.86 | L3MBTL1 (0.63) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL29961431 | 0.84 | ITGA4 (0.62) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL24008794 | 0.84 | ITGA4 (0.62) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL23355185 | 0.81 | CAPN1 (0.58) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL23355184 | 0.81 | CAPN1 (0.58) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL24008799 | 0.79 | CAPN1 (0.58) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL29961792 | 0.79 | CAPN1 (0.58) | CAPN1ITGB2ICAM1ITGALPSMB1 | |
| SCHEMBL24010407 | 0.79 | CAPN1 (0.60) | CAPN1ITGB2ICAM1ITGALPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | CAPN1 1/4885ITGB2 2658/4885ICAM1 3654/4885 |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | CAPN1 4/4885ITGB2 2302/4885ICAM1 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.